Celltrion Opens Up Canadian Market For Remsima SC

Launches Subcutaneous Version Of Biosimilar Infliximab Rival To Remicade

Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

Canada Flag Open Door
Celltrion’s launch opens up the Canadian market for Remsima SC • Source: Alamy

Celltrion has opened up another new market for its Remsima SC (infliximab), after introducing the innovative subcutaneous biosimilar rival to Remicade in Canada.

The launch makes good on the Korean firm’s recent promise to introduce Remsima SC in Canada by the end of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.